ARWR Stock Arrowhead Pharmaceuticals (ARWR, $72.14) entered a weekly bullish trend. Expect an Uptrend continuation

GET DAILY SIGNALS

Get AI intraday signals

ARWR - Arrowhead Pharmaceuticals

Bullish Trend Signal

View

Odds of UP Trend

Loading...

Price: $72.14

Daily change: -$0.86 (-1.18%)

Daily volume: 2.3M

Capitalization: $10.1B

Industry: Biotechnology

Arrowhead Pharmaceuticals (ARWR, $72.14) is predicted by A.I.dvisor to grow by to $73.58 or more within the next week. With its winning streak extending for a consecutive week, ARWR is expected to continue climbing following the week-long Uptrend ― the odds of an Uptrend continuation are

ARWR in +5.61% Uptrend, rising for three consecutive days on February 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARWR advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 22, 2026. You may want to consider a long position or call options on ARWR as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on February 02, 2026. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 205 cases where ARWR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARWR broke above its upper Bollinger Band on February 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.645) is normal, around the industry mean (27.778). P/E Ratio (0.000) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (11.628) is also within normal values, averaging (333.006).